{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:35Z","timestamp":1790710955105,"version":"4.1.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Antiseizure medications (ASM) exhibit considerable interindividual variability in terms of efficacy and adverse events. Genetic variation is thought to contribute to these differences in clinical outcomes. Specifically, the response to valproic acid (VPA), a widely used ASM, is influenced by multiple pharmacogenetic factors. However, and in contrast to other ASMs such as phenytoin and carbamazepine, there is a paucity of data on the association between VPA and various gene variants. The aim of this study was hence to evaluate the influence of candidate pharmacogenetic variants on VPA efficacy, toxicity and serum concentrations in a homogeneous cohort of patients newly diagnosed with genetic generalized epilepsies (GGE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective cohort study, demographic, clinical and treatment outcomes of GGE patients were retrieved from their medical records. Whole exome sequencing was performed in collaboration with Epi25. Gene variants associated with VPA efficacy, metabolism and toxicities were retrieved from PharmGKB. An analysis was then conducted to explore potential associations between these gene variants and VPA clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 166 patients included, 60 (36.1%) experienced treatment failure while 106 (63.9%) achieved treatment success. After adjusting for VPA maintenance dose, carriers of the rs3892097 (<jats:italic>CYP2D6<\/jats:italic>) variant were 2.5 times more likely to experience treatment failure compared to wildtype (<jats:italic>p<\/jats:italic> = 0.026). The rs1057910 variant (<jats:italic>CYP2C9*3<\/jats:italic>) was associated with increased serum VPA concentrations (<jats:italic>p<\/jats:italic> = 0.034). Moreover, the rs1137101 variant (<jats:italic>LEPR gene<\/jats:italic>, a metabolism regulator) was significantly associated with a higher risk of weight gain (regression coefficient of 3.430 [0.674; 6.186], <jats:italic>p<\/jats:italic> = 0.015) and a higher frequency of hair loss (OR = 3.394 [1.157; 9.956], <jats:italic>p<\/jats:italic> = 0.026), while the rs4480 variant (SOD2 gene, encoding for a mitochondrial scavenging enzyme) was correlated with a lower frequency of hair loss (OR = 0.276 [0.089; 0.858], <jats:italic>p<\/jats:italic> = 0.026).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings highlight the role of genetic factors in VPA treatment and underscore the potential for developing therapeutic strategies to enhance patient outcomes and minimize adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1483723","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:31:54Z","timestamp":1730295114000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of candidate pharmacogenetic variants in determining valproic acid efficacy, toxicity and concentrations in patients with epilepsy"],"prefix":"10.3389","volume":"15","author":[{"given":"Hady","family":"Yazbeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Nasreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"El Kurdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Zgheib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neulet.2017.01.014","article-title":"Pharmacogenomics in epilepsy","volume":"667","author":"Balestrini","year":"2018","journal-title":"Neurosci. Lett."},{"key":"B3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"B\u0171di","year":"2015","journal-title":"Epilepsia"},{"key":"B4","unstructured":"CYP2C9 cytochrome P450 family 2 subfamily C member 9 [Homo sapiens (human)] - gene - NCBI2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0142408","DOI":"10.1371\/journal.pone.0142408","article-title":"Polymorphic variants of SCN1A and EPHX1 influence plasma carbamazepine concentration, metabolism and pharmacoresistance in a population of Kosovar Albanian epileptic patients","volume":"10","author":"Daci","year":"2015","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"giab008","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"Gigascience"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(06)68477-8","article-title":"Adult epilepsy","volume":"367","author":"Duncan","year":"2006","journal-title":"Lancet"},{"key":"B8","unstructured":"Epi25 collaborative2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ajhg.2021.04.009","article-title":"Sub-genic intolerance, ClinVar, and the epilepsies: a whole-exome sequencing study of 29,165 individuals","volume":"108","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"B10","unstructured":"Genome aggregation database (gnomAD) - registry of open data on AWS2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharmacogenet Genomics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eplepsyres.2003.12.008","article-title":"Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport","volume":"58","author":"Gibbs","year":"2004","journal-title":"Epilepsy Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1528-1157.1979.tb04808.x","article-title":"Sodium valproate, serum level and clinical effect in epilepsy: a controlled study","volume":"20","author":"Gram","year":"1979","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/epi.17236","article-title":"ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Hirsch","year":"2022","journal-title":"Epilepsia"},{"key":"B15","unstructured":"2024"},{"key":"B16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0304-4165(90)90079-c","article-title":"The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase","volume":"1034","author":"Ito","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"B17","doi-asserted-by":"publisher","first-page":"261497","DOI":"10.1155\/2013\/261497","article-title":"Increased occurrence of valproic acid-induced hyperammonemia in carriers of T1405N polymorphism in carbamoyl phosphate synthetase 1 gene","author":"Janicki","year":"2013","journal-title":"ISRN Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1111\/epi.17671","article-title":"Risk of recurrence in patients with an unprovoked tonic-clonic seizure and generalized epileptiform discharges on EEG","volume":"64","author":"Jomaa","year":"2023","journal-title":"Epilepsia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/ijt.ijt_10_18","article-title":"Valproate: it\u2019s effects on hair","volume":"10","author":"Kakunje","year":"2018","journal-title":"Int. J. Trichology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","article-title":"Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype","volume":"94","author":"Kiang","year":"2006","journal-title":"Toxicol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5021\/ad.2013.25.4.405","article-title":"Analysis of serum zinc and copper concentrations in hair loss","volume":"25","author":"Kil","year":"2013","journal-title":"Ann. Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1034\/j.1600-0447.2001.00299.x","article-title":"CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages","volume":"104","author":"Kirchheiner","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"B24","doi-asserted-by":"publisher","first-page":"113784","DOI":"10.1016\/j.jep.2021.113784","article-title":"Pharmacodynamic and pharmacokinetic interactions of hydroalcoholic leaf extract of Centella asiatica with valproate and phenytoin in experimental models of epilepsy in rats","volume":"270","author":"Kumar","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2217\/pgs.09.32","article-title":"Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese","volume":"10","author":"Kwan","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B26","unstructured":"LEPR leptin receptor Homo sapiens human - gene - NCBI2024"},{"key":"B27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"pyv021","DOI":"10.1093\/ijnp\/pyv021","article-title":"Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid","volume":"18","author":"Li","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.pharep.2017.01.007","article-title":"Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy","volume":"69","author":"L\u00f3pez-Garc\u00eda","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","article-title":"The clinical impact of pharmacogenetics on the treatment of epilepsy","volume":"50","author":"Loscher","year":"2009","journal-title":"Epilepsia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1038\/s41467-023-39539-6","article-title":"Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals","volume":"14","author":"Montanucci","year":"2023","journal-title":"Nat. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/brain\/awaa171","article-title":"Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17 458 subjects","volume":"143","author":"Niestroj","year":"2020","journal-title":"Brain"},{"key":"B37","unstructured":""},{"key":"B38","article-title":"Valproic acid pathway","year":"","journal-title":"Pharmacodynamics"},{"key":"B39","unstructured":"Valproic acid pathway, pharmacokinetics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1600-0625.2005.00365.x","article-title":"Zinc as an ambivalent but potent modulator of murine hair growth in vivo-preliminary observations","volume":"14","author":"Plonka","year":"2005","journal-title":"Exp. Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2814","DOI":"10.1002\/hup.2814","article-title":"Valproate-associated hair abnormalities: pathophysiology and management strategies","volume":"37","author":"Praharaj","year":"2022","journal-title":"Hum. Psychopharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.clpt.2003.12.015","article-title":"CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study","volume":"75","author":"Rau","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.eplepsyres.2011.10.033","article-title":"Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases","volume":"99","author":"Saruwatari","year":"2012","journal-title":"Epilepsy Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10038-005-0264-6","article-title":"Genetic diversity and new therapeutic concepts","volume":"50","author":"Shastry","year":"2005","journal-title":"J. Hum. Genet."},{"key":"B64","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/metabo13010134","article-title":"Therapeutic and toxic effects of valproic acid metabolites","volume":"13","author":"Shnayder","year":"2023","journal-title":"Metabolites"},{"key":"B45","doi-asserted-by":"publisher","first-page":"a022426","DOI":"10.1101\/cshperspect.a022426","article-title":"Seizures and epilepsy: an overview for neuroscientists","volume":"5","author":"Stafstrom","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/exd.12286","article-title":"Hair cycle control by leptin as a new anagen inducer","volume":"23","author":"Sumikawa","year":"2014","journal-title":"Exp. Dermatol."},{"key":"B47","unstructured":"SOD1 superoxide dismutase 1 [Homo sapiens (human)] - gene - NCBI"},{"key":"B48","unstructured":"SOD2 superoxide dismutase 2 [Homo sapiens (human)] - gene - NCBI"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e27213","DOI":"10.1016\/j.heliyon.2024.e27213","article-title":"Meta-analysis investigating the impact of the LEPR rs1137101 (A>G) polymorphism on obesity risk in Asian and Caucasian ethnicities","volume":"10","author":"Supti","year":"2024","journal-title":"Heliyon"},{"key":"B50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.fpc.0000054067.64000.8f","article-title":"The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria","volume":"13","author":"Sutton","year":"2003","journal-title":"Pharmacogenetics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/0974-7753.51923","article-title":"Oxidative stress in ageing of hair","volume":"1","author":"Tr\u00fceb","year":"2009","journal-title":"Int. J. Trichology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/ics.12736","article-title":"Oxidative stress and its impact on skin, scalp and hair","volume":"43","author":"Tr\u00fceb","year":"2021","journal-title":"Int. J. Cosmet. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF00228395","article-title":"Valproate and sodium currents in cultured hippocampal neurons","volume":"93","author":"Van den Berg","year":"1993","journal-title":"Exp. Brain Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"11.10.1","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr. Protoc. Bioinforma."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2302520","DOI":"10.1080\/07853890.2024.2302520","article-title":"Genetic predisposition of LEPR (rs1137101) gene polymorphism related to type 2 diabetes mellitus \u2013 a meta-analysis","volume":"55","author":"Veerabathiran","year":"2023","journal-title":"Ann. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.eplepsyres.2007.11.005","article-title":"Increased oxidative stress in epileptic children treated with valproic acid","volume":"78","author":"Verrotti","year":"2008","journal-title":"Epilepsy Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clpt.2004.01.002","article-title":"Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?","volume":"75","author":"Wedlund","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"B60","volume-title":"Fitzpatrick\u2019s dermatology in general medicine","author":"Wolff","year":"2008"},{"key":"B61","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00228-020-02872-6","article-title":"Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis","volume":"76","author":"Yoon","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/ph16111536","article-title":"Association of ABCB1 polymorphisms with efficacy and adverse drug reactions of valproic acid in children with epilepsy","volume":"16","author":"Zhu","year":"2023","journal-title":"Pharm. (Basel)."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1483723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T13:32:00Z","timestamp":1730295120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1483723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":63,"alternative-id":["10.3389\/fphar.2024.1483723"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1483723","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1483723"}}